Comparison of Prognostic Performance of 8th and 7th Edition of AJCC Staging System for Patients With Gallbladder Cancer Undergoing Curative Intent Surgery.
AJCC
TNM
gallbladder cancer
prognostic performance
staging
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
10 Sep 2024
10 Sep 2024
Historique:
received:
18
06
2024
accepted:
26
06
2024
medline:
11
9
2024
pubmed:
11
9
2024
entrez:
11
9
2024
Statut:
aheadofprint
Résumé
We compared the predictive performance of the 7th and 8th editions of the AJCC staging systems in stratifying disease-related survival outcomes in patients with GBC undergoing curative intent surgery. Patients that underwent curative intent surgery for GBC at our institution (2014 and 2021) were included in the study. Various clinico-pathological data were extracted to perform Kaplan-Meier survival analysis. A total of 240 patients were included in the study. Both, TNM-7, and TNM-8 staging systems can stratify patients into stages with statistically significant differences in disease-free and overall survival. Survival rates drop with stage progression. Using TNM-8, 8/240 (3.33%) patients were upstaged from Stage IIIB (TNM-7) to IVB (TNM-8) and 12/240 (5%) were down-staged from Stage IVB(TNM-7) to IIIB(TNM-8). Survival curves of the re-classified patients matched those of the corresponding TNM-8 stage. Additionally, there was statistically significant difference in their survival (p < 0.001) compared to their corresponding TNM-7 stage. There was no statistically significant difference in survival rates between stages IIA, IIB (TNM-8), and stage II (TNM-7). However, stage IIA had a slightly better survival than stage IIB. Though both TNM-7 and TNM-8 are useful for stratifying patients with GBC, TNM-8 has a better prognostic performance than TNM-7.
Sections du résumé
BACKGROUND
BACKGROUND
We compared the predictive performance of the 7th and 8th editions of the AJCC staging systems in stratifying disease-related survival outcomes in patients with GBC undergoing curative intent surgery.
METHODS
METHODS
Patients that underwent curative intent surgery for GBC at our institution (2014 and 2021) were included in the study. Various clinico-pathological data were extracted to perform Kaplan-Meier survival analysis.
RESULTS
RESULTS
A total of 240 patients were included in the study. Both, TNM-7, and TNM-8 staging systems can stratify patients into stages with statistically significant differences in disease-free and overall survival. Survival rates drop with stage progression. Using TNM-8, 8/240 (3.33%) patients were upstaged from Stage IIIB (TNM-7) to IVB (TNM-8) and 12/240 (5%) were down-staged from Stage IVB(TNM-7) to IIIB(TNM-8). Survival curves of the re-classified patients matched those of the corresponding TNM-8 stage. Additionally, there was statistically significant difference in their survival (p < 0.001) compared to their corresponding TNM-7 stage. There was no statistically significant difference in survival rates between stages IIA, IIB (TNM-8), and stage II (TNM-7). However, stage IIA had a slightly better survival than stage IIB.
CONCLUSION
CONCLUSIONS
Though both TNM-7 and TNM-8 are useful for stratifying patients with GBC, TNM-8 has a better prognostic performance than TNM-7.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
P. Rawla, T. Sunkara, K. C. Thandra, and A. Barsouk, “Epidemiology of Gallbladder Cancer,” Clinical and Experimental Hepatology 5, no. 2 (2019): 93–102.
H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209–249.
Z. I. Hu and K.‐H. Lim, “Evolving Paradigms in the Systemic Treatment of Advanced Gallbladder Cancer: Updates in Year 2022,” Cancers 14, no. 5 (2022): 1249.
M. B. Amin, F. L. Greene, S. B. Edge, et al., “The Eighth Edition Ajcc Cancer Staging Manual: Continuing to Build a Bridge From a Population‐Based to a More “Personalized” Approach to Cancer Staging,” CA: a cancer journal for clinicians 67, no. 2 (2017): 93–99.
American Joint Committee on Cancer, “Gallbladder: Carcinoid Tumors and Sarcomas Are not Included,” in AJCC Cancer Staging Manual, 6th ed. (New York: Springer, 2002), 139–144.
S. Holm, “A Simple Sequentially Rejective Multiple Test Procedure,” Scandinavian Journal of Statistics 6, no. 2 (1979): 65–70.
P. F. Denoix, “[Note on the Possible Role of the International Union against Cancer in Nomenclature, Classification, Analytical Index, Bibliography and Documentation],” Acta‐Unio Internationalis Contra Cancrum 8, no. Special No (1952): 92–96.
J. Shindoh, X. De Aretxabala, T. A. Aloia, et al., “Tumor Location Is a Strong Predictor of Tumor Progression and Survival in t2 Gallbladder Cancer: An International Multicenter Study,” Annals of surgery 261, no. 4 (2015): 733–739.
T. Wakai, Y. Shirai, J. Sakata, M. Nagahashi, Y. Ajioka, and K. Hatakeyama, “Mode of Hepatic Spread From Gallbladder Carcinoma: an Immunohistochemical Analysis of 42 Hepatectomized Specimens,” American Journal of Surgical Pathology 34, no. 1 (2010): 65–74.
Y. Shirai, K. Tsukada, T. Ohtani, H. Watanabe, and K. Hatakeyama, “Hepatic Metastases From Carcinoma of the Gallbladder,” Cancer 75, no. 8 (1995): 2063–2068.
I. Endo, H. Shimada, A. Takimoto, et al., “Microscopic Liver Metastasis: Prognostic Factor for Patients With pt2 Gallbladder Carcinoma,” World Journal of Surgery 28 (2004): 692–696.
J. Sakata, Y. Shirai, T. Wakai, Y. Ajioka, and K. Hatakeyama, “Number of Positive Lymph Nodes Independently Determines the Prognosis After Resection in Patients With Gallbladder Carcinoma,” Annals of Surgical Oncology 17 (2010): 1831–1840.
Y. Shirai, J. Sakata, T. Wakai, T. Ohashi, Y. Ajioka, and K. Hatakeyama, “Assessment of Lymph Node Status in Gallbladder Cancer: Location, Number, or Ratio of Positive Nodes,” World Journal of Surgical Oncology 10 (2012): 87.
H. Shimada, I. Endo, Y. Fujii, et al., “Appraisal of Surgical Resection of Gallbladder Cancer With Special Reference to Lymph Node Dissection,” Langenbeck's Archives of Surgery 385 (2000): 509–514.
I. Endo, H. Shimada, M. Tanabe, et al., “Prognostic Significance of the Number of Positive Lymph Nodes in Gallbladder Cancer,” Journal of gastrointestinal surgery 10 (2006): 999–1007.
D. Zhang, Y. Zheng, Z. Wang, et al., “Comparison of the 7th and Proposed 8th Editions of the AJCC/UICC TNM Staging System for Esophageal Squamous Cell Carcinoma Underwent Radical Surgery,” European Journal of Surgical Oncology (EJSO) 43, no. 10 (2017): 1949–1955.
S. H. Nam, M. R. Bae, J.‐L. Roh, et al., “A Comparison of the 7th and 8th Editions of the AJCC Staging System in Terms of Predicting Recurrence and Survival in Patients With Papillary Thyroid Carcinoma,” Oral Oncology 87 (2018): 158–164.
C. Neppl, M. D. Keller, A. Scherz, et al., “Comparison of the 7th and 8th Edition of the UICC/AJCC TNM Staging System in Primary Resected Squamous Cell Carcinomas of the Lung—A Single Center Analysis of 354 Cases,” Frontiers in medicine 6 (2019): 196.
P. Mate, A. Agarwal, and A. M. Saifi, “Comparison of AJCC 7th and 8th Edition Staging System in Oral Squamous Cell Carcinoma: A Retrospective Study,” Oral Oncology Reports 6 (2023): 100020.
H. Oweira, A. Mehrabi, A. Giryes, A. Tekbas, and O. Abdel‐Rahman, “External Validation of the 8th American Joint Committee on Cancer Staging System for Gall Bladder Carcinoma,” Journal of gastrointestinal oncology 9, no. 6 (2018): 1084–1090.
Y.‐N. Sung, M. Song, J. H. Lee, et al., “Validation of the 8th Edition of the American Joint Committee on Cancer Staging System for Gallbladder Cancer and Implications for the Follow‐Up of Patients Without Node Dissection,” Cancer Research and Treatment 52, no. 2 (2020): 455–468.
D. Giannis, M. Cerullo, D. Moris, et al., “Validation of the 8th Edition American Joint Commission on Cancer (AJCC) Gallbladder Cancer Staging System: Prognostic Discrimination and Identification of Key Predictive Factors,” Cancers 13, no. 3 (2021): 547.